Insurers’ decisions about which services to cover are often based on economic models that are seemingly objective but neglect factors affecting people who are economically disadvantaged.
AMA J Ethics. 2021;23(8):E648-652. doi:
10.1001/amajethics.2021.648.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Weyinshet Gossa, MD, MPH and Michael D. Fetters, MD, MPH, MA
Cervical cancer has become rare in high-income countries but is a leading cause of mortality among women in low- and middle-income countries. This inequity is an epidemiological tragedy.
AMA J Ethics. 2020;22(2):E126-134. doi:
10.1001/amajethics.2020.126.
Dr Christopher Whaley joins Ethics Talk to discuss his article, coauthored with Dr Austin Frakt: “If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important?”
Dr Kevin Schulman joins Ethics Talk to discuss his article, coauthored with Dr Barak Richman: “Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm.”